Evidence map›Paper›PMID 29723101›Full record

ReviewCancer biology & therapy2018

Breast cancer in an 18-year-old female: A fatal case report and literature review.

Maciej Jóźwik, Renata Posmyk, Marcin Jóźwik, Andrzej Semczuk, Magdalena Gogiel-Shields, Marta Kuś-Słowińska, Magdalena Garbowicz, Mark Klukowski, Jacek Wojciechowicz

Open access · bronzeAbstract readCase ReportsReview
In one paragraph

Review in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. TheBreast care (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Maciej Jóźwika Department of Gynecology and Gynecologic Oncology , Medical University of Białystok , Białystok , Poland.ORCID 0000-0001-9182-8791
Renata Posmyka Department of Gynecology and Gynecologic Oncology , Medical University of Białystok , Białystok , Poland.
Marcin Jóźwikb Department of Gynecology and Obstetrics, Faculty of Medicine , University of Warmia and Mazury , Olsztyn , Poland.
Andrzej Semczukc II Department of Gynecology , Medical University of Lublin , Lublin , Poland.
Magdalena Gogiel-Shieldsd West Midlands Regional Genetics Laboratory , Birmingham Women's NHS Foundation Trust , Birmingham , UK.
Marta Kuś-Słowińskae Medical Genetics Laboratory, DNA Research Center , Poznań , Poland.
Magdalena Garbowicze Medical Genetics Laboratory, DNA Research Center , Poznań , Poland.
Mark Klukowskig Department of Pediatrics, Gastroenterology and Allergology , Medical University of Białystok , Białystok , Poland.
Jacek Wojciechowicze Medical Genetics Laboratory, DNA Research Center , Poznań , Poland.
Medical University of Białystok · PLAdam Mickiewicz University in Poznań · PLMedical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the most frequent malignancy in both pre- and postmenopausal women. However, it is exceedingly rare in very young patients, and especially in adolescents. Herein, we report a case of an 18-year-old female diagnosed with invasive BC. The proband had been found to be negative for BC in close family members. A common BC genetic screening test for the Polish population did not detect any known founder mutations in the BRCA1 gene. Further evaluation identified a p.Ile157Thr (I157T) mutation in the CHEK2 gene, a p.Ala1991Val (A1991V) variant of unknown significance in the BRCA2 gene, p.Lys751Gln (K751Q) variant in the XPD (ERCC2) gene, and a homozygous p.Glu1008Ter (E1008*) mutation in the NOD2 gene. No other mutation had been found by next generation sequencing in major BC high-risk susceptibility genes BRCA1, BRCA2, as well as 92 other genes. To date, all these found alterations have been considered as low to moderate risk factors in the general population and moderate risk factors in younger women (<35 years of age). There are no previous articles relating low and moderate risk gene mutations to very young onset (below 20 years) BC with a fatal outcome. In our patient, a possible cumulative or synergistic risk effect for these 4 alterations, and a mutation in the NOD2 gene in particular, of which both presumably healthy parents were found to be carriers, is suggested.

Indexed as

Genetic Predisposition to DiseaseAdolescentAntineoplastic Combined Chemotherapy ProtocolsBRCA2 ProteinBreast NeoplasmsCheckpoint Kinase 2CyclophosphamideDoxorubicinFatal OutcomeFemaleGenetic Carrier ScreeningHeterozygoteHumansLiver NeoplasmsLung NeoplasmsMultiple Organ FailureBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanCyclophosphamideDoxorubicinERCC2 protein, humanNOD2 protein, humanNod2 Signaling Adaptor ProteinTaxoidsXeroderma Pigmentosum Group D ProteinadolescentBRCA2 genebreast cancerCHEK2 genenext generation sequencingNOD2 geneXPD gene

Identifiers

PMID29723101
PMCPMC5989804
OpenAlexW2800681200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.